Estamos no ar no ! Saiba mais

Biomea Fusion

BMEA

Valor de mercado US$ 63 mi

0,8689 USD

+0,0325

3,89%

No fechamento Atualizado 16 de out. 16:00 EDT

Pré-mercado

Após o fechamento do mercado

0,8609

-0,0080

0,92%

1 dia

3,89%

5 dias

-39,66%

1 mês

-50,06%

3 meses

-31,04%

6 meses

-54,98%

No acumulado do ano

-35,16%

1 ano

-45,35%

5 anos

-92,44%

10 anos

-95,33%

Sobre: Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Funcionários: 37

Saúde Biotecnologia

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 20%

Neutro 66,7%

Negativo 13,3%

State Street, Fastenal And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Dow futures gaining around 150 points on Wednesday.

State Street, Fastenal And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study

Biomea Fusion NASDAQ: BMEA reported top-line results from a Phase Ib multiple ascending-dose study of BMF-650, an investigational oral small-molecule GLP-1 receptor agonist being developed for weight management. The company said the 28-day study showed weight reduction across active-treatment cohorts, while reported gastrointestinal adverse events were mild or moderate.

Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study

Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript

Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript

Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript

Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist

SAN CARLOS, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company, today announced Phase 1 GLP-131 clinical trial results for BMF-650, its investigational oral small-molecule glucagon-like peptide-1 receptor agonist (“GLP-1 RA”), which demonstrated consistent weight reduction across five multiple ascending dose (“MAD”) cohorts over four weeks and encouraging tolerability even when reaching 400 mg QD in the highest dosing cohort after only a single one-week titration step. Together, these findings provide encouraging early evidence of BMF-650's clinical activity, sustained weight-reduction trajectory, and, importantly, it's tolerability.

Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

Company to host conference call and webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT) Company to host conference call and webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT)

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data

Biomea Fusion, Inc. (NASDAQ:BMEA) shares are trading lower by almost 19% on Wednesday as investors digest the company's decision to terminate its proposed public offering.

Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data

Biomea Fusion Announces Termination of Proposed Public Offering of Securities

SAN CARLOS, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has terminated its proposed public offering of securities, previously announced on September 22, 2026. The termination results from an assessment by the Company's management that current market conditions are not conducive for an offering on terms that would be in the best interests of the Company's stockholders. No securities were sold in connection with the proposed offering.

Biomea Fusion Announces Termination of Proposed Public Offering of Securities

Biomea Fusion Announces Proposed Public Offering of Securities

SAN CARLOS, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Biomea intends to grant the underwriter a 30-day option to purchase up to an additional fifteen percent (15%) of the total number of shares of common stock and pre-funded warrants in the proposed offering. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering are to be sold by Biomea.

Biomea Fusion Announces Proposed Public Offering of Securities

Zacks Investment Research

After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright

Biomea Fusion, Inc. (BMEA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, BMEA's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright

Biomea Fusion to Participate in Upcoming Investor Conferences

SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Company” or “Company management”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that members of its management team will participate in the following upcoming investor conferences: Citi's 2026 Biopharma Back to School Conference: Biomea will participate in one-on-one investor meetings on September 10, 2026, in New York, NY.

Biomea Fusion to Participate in Upcoming Investor Conferences

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™